New Protocol: TFOX for Advanced Gastric Cancer

Study

Phase 3, open-label, multicenter randomized trial (PRODIGE 51- FFCD-GASTFOX)

Pts with previously untreated advanced HER2-negative gastric/GEJ adenocarcinoma

TFOX (docetaxel + oxaliplatin + leucovorin + 5-FU) vs. FOLFOX

Efficacy

ORR: 62.3% vs. 53.4% (TFOX vs. FOLFOX)

CR: 6% vs. 6%

mPFS: 7.6 mos vs. 6.0 mos (p = 0.007)

mOS: 15.1 mos vs. 12.7 mos

Safety

Grade ≥3 AEs: neutropenia (27% vs. 18%), diarrhea (15% vs. 7%), neuropathy (32% vs. 20%)

Lancet Oncol 2025; published online Apr 23

Zaanan A,Bouche O,de la Fouchardière C TFOX versus FOLFOX in first-line treatment of patients with advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (PRODIGE 51- FFCD-GASTFOX): an open-label, multicentre, randomised, phase 3 trial

http://doi.org/10.1016/S1470-2045(24)00545-1

Reviewed by Ulas D. Bayraktar, MD on May 5, 2025

Back to top Drag